The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report

BACKGROUND: There are currently no approved medications for impaired social cognition and function, core symptoms of autism spectrum disorder. We describe marked improvement of these symptoms with long-term low-dose administration of the partial µ-opioid agonist buprenorphine. We discuss these obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoglund, Charlotte, Leknes, Siri, Heilig, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011926/
https://www.ncbi.nlm.nih.gov/pubmed/35422015
http://dx.doi.org/10.1186/s13256-022-03384-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011926/
https://www.ncbi.nlm.nih.gov/pubmed/35422015
http://dx.doi.org/10.1186/s13256-022-03384-w

Ejemplares similares